{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:51:53Z","timestamp":1771048313766,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Treatment response and resistance in major depressive disorder (MDD) show a significant genetic component, but previous studies had limited power also due to MDD heterogeneity. This literature review focuses on the genetic factors associated with treatment outcomes in MDD, exploring their overlap with those associated with clinically relevant symptom dimensions. We searched PubMed for: (1) genome-wide association studies (GWASs) or whole exome sequencing studies (WESs) that investigated efficacy outcomes in MDD; (2) studies examining the association between MDD treatment outcomes and specific depressive symptom dimensions; and (3) GWASs of the identified symptom dimensions. We identified 13 GWASs and one WES of treatment outcomes in MDD, reporting several significant loci, genes, and gene sets involved in gene expression, immune system regulation, synaptic transmission and plasticity, neurogenesis and differentiation. Nine symptom dimensions were associated with poor treatment outcomes and studied by previous GWASs (anxiety, neuroticism, anhedonia, cognitive functioning, melancholia, suicide attempt, psychosis, sleep, sociability). Four genes were associated with both treatment outcomes and these symptom dimensions: <jats:italic>CGREF1<\/jats:italic> (anxiety); <jats:italic>MCHR1<\/jats:italic> (neuroticism); <jats:italic>FTO<\/jats:italic> and <jats:italic>NRXN3<\/jats:italic> (sleep). Other overlapping signals were found when considering genes suggestively associated with treatment outcomes. Genetic studies of treatment outcomes showed convergence at the level of biological processes, despite no replication at gene or variant level. The genetic signals overlapping with symptom dimensions of interest may point to shared biological mechanisms and potential targets for new treatments tailored to the individual patient\u2019s clinical profile.<\/jats:p>","DOI":"10.1007\/s00406-024-01873-1","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:02:33Z","timestamp":1724760153000},"page":"1637-1651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?"],"prefix":"10.1007","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6913-9657","authenticated-orcid":false,"given":"Alfonso","family":"Martone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6187-0187","authenticated-orcid":false,"given":"Chiara","family":"Possidente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-563X","authenticated-orcid":false,"given":"Giuseppe","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0276-7865","authenticated-orcid":false,"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-3759","authenticated-orcid":false,"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1873_CR1","unstructured":"W. World Health Organization (2023) Depression. https:\/\/www.who.int\/health-topics\/depression#tab=tab_1. Accessed 31 May 2024"},{"key":"1873_CR2","volume-title":"Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry","author":"BJ Sadock","year":"2017","unstructured":"Sadock BJ, Sadock VA, Ruiz P, Kaplan HI (2017) Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry. Wolters Kluwer Health\/Lippincott Williams & Wilkins, Philadelphia"},{"key":"1873_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/9781119870203","volume-title":"In Maudsley Prescribing Guidelines in Psychiatry","author":"DM Taylor","year":"2021","unstructured":"Taylor DM, Barnes TR, Young AH (2021) In Maudsley Prescribing Guidelines in Psychiatry, 14th edn. Wiley Blackwell, Hoboken","edition":"14"},{"issue":"2","key":"1873_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN et al (2018) Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20(2):97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609","journal-title":"Bipolar Disord"},{"issue":"2","key":"1873_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/pharmacy6020043","volume":"6","author":"AV Fuentes","year":"2018","unstructured":"Fuentes AV, Pineda MD, Venkata KCN (2018) Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharm (Basel) 6(2):43. https:\/\/doi.org\/10.3390\/pharmacy6020043","journal-title":"Pharm (Basel)"},{"issue":"3","key":"1873_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/070674371005500303","volume":"55","author":"M Sinyor","year":"2010","unstructured":"Sinyor M, Schaffer A, Levitt A (2010) The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry 55(3):126\u2013135. https:\/\/doi.org\/10.1177\/070674371005500303","journal-title":"Can J Psychiatry"},{"issue":"11","key":"1873_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. AJP 163(11):1905\u20131917. https:\/\/doi.org\/10.1176\/ajp.2006.163.11.1905","journal-title":"AJP"},{"issue":"6","key":"1873_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR (2007) The STAR* D project results: a comprehensive review of findings. Curr Psychiatry Rep 9(6):449\u2013459","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"1873_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS et al (2023) Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22(3):394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120","journal-title":"World Psychiatry"},{"issue":"3","key":"1873_CR10","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41380-021-01381-x","volume":"27","author":"L Sforzini","year":"2022","unstructured":"Sforzini L et al (2022) A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry 27(3):1286\u20131299. https:\/\/doi.org\/10.1038\/s41380-021-01381-x","journal-title":"Mol Psychiatry"},{"key":"1873_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110266","volume":"109","author":"V Oliva","year":"2021","unstructured":"Oliva V et al (2021) Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 109:110266","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"1873_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4088\/JCP.09r05346blu","volume":"71","author":"A Serretti","year":"2010","unstructured":"Serretti A, Mandelli L, Laura M (2010) Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71(10):979","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1873_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0022-3956(98)00004-1","volume":"32","author":"L Franchini","year":"1998","unstructured":"Franchini L, Serretti A, Gasperini M, Smeraldi E (1998) Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32(5):255\u2013259","journal-title":"J Psychiatr Res"},{"issue":"2","key":"1873_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bpsgos.2021.07.008","volume":"2","author":"O Pain","year":"2021","unstructured":"Pain O et al (2021) Identifying the common genetic basis of antidepressant response. Biol Psychiatry Glob Open Sci 2(2):115\u2013126. https:\/\/doi.org\/10.1016\/j.bpsgos.2021.07.008","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"1873_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.psychres.2016.04.034","volume":"240","author":"V De Carlo","year":"2016","unstructured":"De Carlo V, Calati R, Serretti A (2016) Socio-demographic and clinical predictors of non-response\/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res 240:421\u2013430. https:\/\/doi.org\/10.1016\/j.psychres.2016.04.034","journal-title":"Psychiatry Res"},{"issue":"1","key":"1873_CR16","first-page":"14989","volume":"79","author":"A Kautzky","year":"2017","unstructured":"Kautzky A et al (2017) Refining prediction in treatment-resistant depression: results of machine learning analyses in the TRD III sample. J Clin Psychiatry 79(1):14989","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1873_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ijnp\/pyy024","volume":"22","author":"C Fabbri","year":"2019","unstructured":"Fabbri C et al (2019) The genetics of treatment-resistant depression: a critical review and future perspectives. Int J Neuropsychopharmacol 22(2):93\u2013104","journal-title":"Int J Neuropsychopharmacol"},{"key":"1873_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jad.2014.10.010","volume":"172","author":"EI Fried","year":"2015","unstructured":"Fried EI, Nesse RM (2015) Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord 172:96\u2013102. https:\/\/doi.org\/10.1016\/j.jad.2014.10.010","journal-title":"J Affect Disord"},{"issue":"12","key":"1873_CR19","doi-asserted-by":"publisher","first-page":"8450","DOI":"10.4088\/JCP.09m05398blu","volume":"71","author":"F Lamers","year":"2010","unstructured":"Lamers F et al (2010) Identifying depressive subtypes in a large cohort study: results from the Netherlands study of depression and anxiety (NESDA). J Clin Psychiatry 71(12):8450","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1873_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1017\/S0033291720002342","volume":"52","author":"I Badini","year":"2022","unstructured":"Badini I et al (2022) Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. Psychol Med 52(4):726\u2013736. https:\/\/doi.org\/10.1017\/S0033291720002342","journal-title":"Psychol Med"},{"issue":"4","key":"1873_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/mp.2015.86","volume":"21","author":"Y Milaneschi","year":"2016","unstructured":"Milaneschi Y et al (2016) Polygenic dissection of major depression clinical heterogeneity. Mol Psychiatry 21(4):516\u2013522","journal-title":"Mol Psychiatry"},{"issue":"14","key":"1873_CR22","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1017\/S0033291719002526","volume":"50","author":"JG Thorp","year":"2020","unstructured":"Thorp JG, Marees AT, Ong J-S, An J, MacGregor S, Derks EM (2020) Genetic heterogeneity in self-reported depressive symptoms identified through genetic analyses of the PHQ-9. Psychol Med 50(14):2385\u20132396","journal-title":"Psychol Med"},{"issue":"5","key":"1873_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1176\/appi.ajp.2018.18070881","volume":"176","author":"R Border","year":"2019","unstructured":"Border R et al (2019) No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. Am J Psychiatry 176(5):376\u2013387. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18070881","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1873_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/15622975.2016.1208843","volume":"18","author":"C Fabbri","year":"2017","unstructured":"Fabbri C et al (2017) Consensus paper of the WFSBP task force on genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry 18(1):5\u201328. https:\/\/doi.org\/10.1080\/15622975.2016.1208843","journal-title":"World J Biol Psychiatry"},{"issue":"D1","key":"1873_CR25","doi-asserted-by":"publisher","first-page":"D1227","DOI":"10.1093\/nar\/gkad1040","volume":"52","author":"M Cannon","year":"2024","unstructured":"Cannon M et al (2024) DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms. Nucl Acids Res 52(D1):D1227\u2013D1235. https:\/\/doi.org\/10.1093\/nar\/gkad1040","journal-title":"Nucl Acids Res"},{"key":"1873_CR26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.10.22278630","author":"J Kang","year":"2023","unstructured":"Kang J et al (2023) Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits. MedRxiv. https:\/\/doi.org\/10.1101\/2022.08.10.22278630","journal-title":"MedRxiv"},{"key":"1873_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114972","volume":"319","author":"Y Huang","year":"2023","unstructured":"Huang Y et al (2023) Comparison on the clinical features in patients with or without treatment-resistant depression: a national survey on symptomatology of depression report. Psychiatry Res 319:114972. https:\/\/doi.org\/10.1016\/j.psychres.2022.114972","journal-title":"Psychiatry Res"},{"issue":"5","key":"1873_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1017\/S0033291711001905","volume":"42","author":"R Uher","year":"2012","unstructured":"Uher R et al (2012) Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 42(5):967\u2013980. https:\/\/doi.org\/10.1017\/S0033291711001905","journal-title":"Psychol Med"},{"key":"1873_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2202-4-19","volume":"4","author":"L Verret","year":"2003","unstructured":"Verret L et al (2003) A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci 4:19. https:\/\/doi.org\/10.1186\/1471-2202-4-19","journal-title":"BMC Neurosci"},{"issue":"1","key":"1873_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2006.04.043","volume":"540","author":"AM Basso","year":"2006","unstructured":"Basso AM et al (2006) Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur J Pharmacol 540(1):115\u2013120. https:\/\/doi.org\/10.1016\/j.ejphar.2006.04.043","journal-title":"Eur J Pharmacol"},{"key":"1873_CR31","unstructured":"Squibb B-M (2015) Randomized, double-blind, placebo-controlled, ascending multiple-dose and parallel arm study to evaluate the safety, pharmacokinetics and pharmacodynamics of BMS-830216 (prodrug of BMS-819881) in obese subjects\u2019, clinicaltrials.gov, clinical trial registration NCT00909766. https:\/\/clinicaltrials.gov\/study\/NCT00909766. Accessed 01 Jan 2024"},{"key":"1873_CR32","unstructured":"PubChem FTO - FTO alpha-ketoglutarate dependent dioxygenase (human). https:\/\/pubchem.ncbi.nlm.nih.gov\/gene\/FTO\/human. Accessed 20 May 2024"},{"issue":"1","key":"1873_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1288-1061","volume":"54","author":"CA Bousman","year":"2021","unstructured":"Bousman CA et al (2021) Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry 54(1):5\u201317. https:\/\/doi.org\/10.1055\/a-1288-1061","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"1873_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41397-019-0067-3","volume":"20","author":"EM Wigmore","year":"2020","unstructured":"Wigmore EM et al (2020) Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics J 20(2):329\u2013341. https:\/\/doi.org\/10.1038\/s41397-019-0067-3","journal-title":"Pharmacogenomics J"},{"key":"1873_CR35","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.29.24306535","author":"MJ Adams","year":"2024","unstructured":"Adams MJ, Lewis CM, McIntosh AM, the P. G. C. M. D. D. W. Group (2024) Genome-wide study of major depression in 685,808 diverse individuals identifies 697 independent associations, infers causal neuronal subtypes and biological targets for novel pharmacotherapies. MedRxiv. https:\/\/doi.org\/10.1101\/2024.04.29.24306535","journal-title":"MedRxiv"},{"issue":"7","key":"1873_CR36","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1007\/s12035-016-0032-y","volume":"54","author":"F Ferrari","year":"2017","unstructured":"Ferrari F, Villa RF (2017) The neurobiology of depression: an integrated overview from biological theories to clinical evidence. Mol Neurobiol 54(7):4847\u20134865. https:\/\/doi.org\/10.1007\/s12035-016-0032-y","journal-title":"Mol Neurobiol"},{"issue":"7215","key":"1873_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nature07455","volume":"455","author":"V Krishnan","year":"2008","unstructured":"Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455(7215):894\u2013902. https:\/\/doi.org\/10.1038\/nature07455","journal-title":"Nature"},{"key":"1873_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pnpbp.2015.06.001","volume":"64","author":"T Rantam\u00e4ki","year":"2016","unstructured":"Rantam\u00e4ki T, Yalcin I (2016) Antidepressant drug action\u2013from rapid changes on network function to network rewiring. Prog Neuropsychopharmacol Biol Psychiatry 64:285\u2013292. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.06.001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"1873_CR39","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.gendis.2022.04.008","volume":"10","author":"R Zhang","year":"2022","unstructured":"Zhang R, Jiang H, Liu Y, He G (2022) Structure, function, and pathology of neurexin-3. Genes Dis 10(5):1908\u20131919. https:\/\/doi.org\/10.1016\/j.gendis.2022.04.008","journal-title":"Genes Dis"},{"issue":"6","key":"1873_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000539","volume":"5","author":"NL Heard-Costa","year":"2009","unstructured":"Heard-Costa NL et al (2009) NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE consortium. PLoS Genet 5(6):e1000539. https:\/\/doi.org\/10.1371\/journal.pgen.1000539","journal-title":"PLoS Genet"},{"issue":"23","key":"1873_CR41","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1093\/hmg\/ddm247","volume":"16","author":"A Hishimoto","year":"2007","unstructured":"Hishimoto A et al (2007) Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum Mol Genet 16(23):2880\u20132891. https:\/\/doi.org\/10.1093\/hmg\/ddm247","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1873_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/nar\/gku1276","volume":"43","author":"Y Huang","year":"2015","unstructured":"Huang Y et al (2015) Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res 43(1):373\u2013384. https:\/\/doi.org\/10.1093\/nar\/gku1276","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"1873_CR43","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G et al (2011) N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 7(12):885\u2013887. https:\/\/doi.org\/10.1038\/nchembio.687","journal-title":"Nat Chem Biol"},{"issue":"6","key":"1873_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.molcel.2018.08.011","volume":"71","author":"J Wei","year":"2018","unstructured":"Wei J et al (2018) Differential m6A, m6Am, and m1A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell 71(6):973-985.e5. https:\/\/doi.org\/10.1016\/j.molcel.2018.08.011","journal-title":"Mol Cell"},{"key":"1873_CR45","unstructured":"MCHR1 melanin concentrating hormone receptor 1 [Homo sapiens (human)]-Gene-NCBI. https:\/\/www.ncbi.nlm.nih.gov\/gene\/2847. Accessed 25 May 2024"},{"issue":"D1","key":"1873_CR46","doi-asserted-by":"publisher","first-page":"D1302","DOI":"10.1093\/nar\/gkaa1027","volume":"49","author":"D Ochoa","year":"2021","unstructured":"Ochoa D et al (2021) Open targets platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res 49(D1):D1302\u2013D1310. https:\/\/doi.org\/10.1093\/nar\/gkaa1027","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1873_CR47","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41588-021-00857-4","volume":"53","author":"N Mullins","year":"2021","unstructured":"Mullins N et al (2021) Genome-wide association study of over 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet 53(6):817. https:\/\/doi.org\/10.1038\/s41588-021-00857-4","journal-title":"Nat Genet"},{"key":"1873_CR48","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.07.24303921","author":"G Fanelli","year":"2024","unstructured":"Fanelli G et al (2024) Local patterns of genetic sharing challenge the boundaries between neuropsychiatric and insulin resistance-related conditions. MedRxiv. https:\/\/doi.org\/10.1101\/2024.03.07.24303921","journal-title":"MedRxiv"},{"issue":"4","key":"1873_CR49","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.120.15605","volume":"76","author":"LV Kessing","year":"2020","unstructured":"Kessing LV, Rytgaard HC, Ekstr\u00f8m CT, Torp-Pedersen C, Berk M, Gerds TA (2020) Antihypertensive drugs and risk of depression: a nationwide population-based study. Hypertension 76(4):1263\u20131279. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15605","journal-title":"Hypertension"},{"key":"1873_CR50","unstructured":"ATC0175 | MCH1R antagonist | MedChemExpress, MedchemExpress.com. https:\/\/www.medchemexpress.com\/atc0175.html. Accessed 25 May 2024"},{"issue":"4","key":"1873_CR51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1527-3458.2005.tb00052.x","volume":"11","author":"S Chaki","year":"2005","unstructured":"Chaki S et al (2005) ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety. CNS Drug Rev 11(4):341\u2013352. https:\/\/doi.org\/10.1111\/j.1527-3458.2005.tb00052.x","journal-title":"CNS Drug Rev"},{"issue":"1","key":"1873_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12885-023-11075-y","volume":"23","author":"M Xiang","year":"2023","unstructured":"Xiang M, Gao Y, Zhou Y, Wang M, Yao X (2023) A novel nomogram based on cell cycle-related genes for predicting overall survival in early-onset colorectal cancer. BMC Cancer 23(1):595. https:\/\/doi.org\/10.1186\/s12885-023-11075-y","journal-title":"BMC Cancer"},{"key":"1873_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s42003-018-0042-6","volume":"1","author":"EAD Clifton","year":"2018","unstructured":"Clifton EAD et al (2018) Genome-wide association study for risk taking propensity indicates shared pathways with body mass index. Commun Biol 1:36. https:\/\/doi.org\/10.1038\/s42003-018-0042-6","journal-title":"Commun Biol"},{"issue":"1","key":"1873_CR54","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.1038\/s41467-023-41394-4","volume":"14","author":"J Lee","year":"2023","unstructured":"Lee J et al (2023) Quantifying the causal impact of biological risk factors on healthcare costs. Nat Commun 14(1):5672. https:\/\/doi.org\/10.1038\/s41467-023-41394-4","journal-title":"Nat Commun"},{"issue":"4","key":"1873_CR55","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41588-022-01016-z","volume":"54","author":"A Okbay","year":"2022","unstructured":"Okbay A et al (2022) Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. Nat Genet 54(4):437\u2013449. https:\/\/doi.org\/10.1038\/s41588-022-01016-z","journal-title":"Nat Genet"},{"issue":"9","key":"1873_CR56","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41562-021-01069-w","volume":"5","author":"Z Sha","year":"2021","unstructured":"Sha Z et al (2021) The genetic architecture of structural left-right asymmetry of the human brain. Nat Hum Behav 5(9):1226\u20131239. https:\/\/doi.org\/10.1038\/s41562-021-01069-w","journal-title":"Nat Hum Behav"},{"issue":"1","key":"1873_CR57","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/s41467-024-46023-2","volume":"15","author":"M Wainberg","year":"2024","unstructured":"Wainberg M et al (2024) Genetic architecture of the structural connectome. Nat Commun 15(1):1962. https:\/\/doi.org\/10.1038\/s41467-024-46023-2","journal-title":"Nat Commun"},{"key":"1873_CR58","unstructured":"EPHB1-ephrin type-B receptor 1-Homo sapiens (Human) | UniProtKB | UniProt. https:\/\/www.uniprot.org\/uniprotkb\/P54762\/entry#function. Accessed 23 May 2024"},{"issue":"4","key":"1873_CR59","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2174\/1570159X1304150831121909","volume":"13","author":"N Dusi","year":"2015","unstructured":"Dusi N, Barlati S, Vita A, Brambilla P (2015) Brain structural effects of antidepressant treatment in major depression. Curr Neuropharmacol 13(4):458\u2013465. https:\/\/doi.org\/10.2174\/1570159X1304150831121909","journal-title":"Curr Neuropharmacol"},{"key":"1873_CR60","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jad.2018.09.067","volume":"243","author":"K Perlman","year":"2019","unstructured":"Perlman K et al (2019) A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord 243:503\u2013515. https:\/\/doi.org\/10.1016\/j.jad.2018.09.067","journal-title":"J Affect Disord"},{"issue":"9","key":"1873_CR61","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/archgenpsychiatry.2009.95","volume":"66","author":"M Ising","year":"2009","unstructured":"Ising M et al (2009) A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66(9):966\u2013975. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2009.95","journal-title":"Arch Gen Psychiatry"},{"key":"1873_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135619","volume":"744","author":"J Kapur","year":"2021","unstructured":"Kapur J, Joshi S (2021) Progesterone modulates neuronal excitability bidirectionally. Neurosci Lett 744:135619. https:\/\/doi.org\/10.1016\/j.neulet.2020.135619","journal-title":"Neurosci Lett"},{"key":"1873_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2019.100198","volume":"11","author":"N Walton","year":"2019","unstructured":"Walton N, Maguire J (2019) Allopregnanolone-based treatments for postpartum depression: why\/how do they work? Neurobiol Stress 11:100198. https:\/\/doi.org\/10.1016\/j.ynstr.2019.100198","journal-title":"Neurobiol Stress"},{"issue":"6","key":"1873_CR64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4196\/kjpp.2016.20.6.557","volume":"20","author":"SJ Kang","year":"2016","unstructured":"Kang SJ, Kaang B-K (2016) Metabotropic glutamate receptor dependent long-term depression in the cortex. Korean J Physiol Pharmacol 20(6):557\u2013564. https:\/\/doi.org\/10.4196\/kjpp.2016.20.6.557","journal-title":"Korean J Physiol Pharmacol"},{"issue":"9","key":"1873_CR65","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH et al (2016) Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder:section 3. Pharmacological treatments. Can J Psychiatry 61(9):540\u2013560. https:\/\/doi.org\/10.1177\/0706743716659417","journal-title":"Can J Psychiatry"},{"issue":"7","key":"1873_CR66","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/jcm10071475","volume":"10","author":"W Kryszkowski","year":"2021","unstructured":"Kryszkowski W, Boczek T (2021) The G protein-coupled glutamate receptors as novel molecular targets in schizophrenia treatment\u2014a narrative review. J Clin Med 10(7):1475. https:\/\/doi.org\/10.3390\/jcm10071475","journal-title":"J Clin Med"},{"key":"1873_CR67","unstructured":"NCATS inxight drugs \u2014 MGS-0210. https:\/\/drugs.ncats.io\/substance\/12XH8EKL2A. Accessed 24 May 2024"},{"issue":"4","key":"1873_CR68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","volume":"46","author":"S Chaki","year":"2004","unstructured":"Chaki S et al (2004) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46(4):457\u2013467. https:\/\/doi.org\/10.1016\/j.neuropharm.2003.10.009","journal-title":"Neuropharmacology"},{"issue":"2","key":"1873_CR69","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","volume":"34","author":"B Hagenbuch","year":"2013","unstructured":"Hagenbuch B, Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34(2):396\u2013412. https:\/\/doi.org\/10.1016\/j.mam.2012.10.009","journal-title":"Mol Aspects Med"},{"key":"1873_CR70","unstructured":"SLCO3A1 protein expression summary-the human protein atlas. https:\/\/www.proteinatlas.org\/ENSG00000176463-SLCO3A1. Accessed 22 May 2024"},{"key":"1873_CR71","unstructured":"SLCO3A1 solute carrier organic anion transporter family member 3A1 [Homo sapiens (human)]-gene-NCBI. https:\/\/www.ncbi.nlm.nih.gov\/gene\/28232. Accessed 22 May 2024"},{"issue":"2","key":"1873_CR72","doi-asserted-by":"publisher","first-page":"C795","DOI":"10.1152\/ajpcell.00597.2005","volume":"292","author":"RD Huber","year":"2007","unstructured":"Huber RD et al (2007) Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 292(2):C795\u2013C806. https:\/\/doi.org\/10.1152\/ajpcell.00597.2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"1873_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2023.140428","volume":"345","author":"T Li","year":"2023","unstructured":"Li T et al (2023) Organic anion transporting polypeptide 3a1 is a novel influx pump for perfluorooctane sulfonate in sertoli cells and contributes to its reproductive toxicity. Chemosphere 345:140428. https:\/\/doi.org\/10.1016\/j.chemosphere.2023.140428","journal-title":"Chemosphere"},{"key":"1873_CR74","unstructured":"Pharmaco-transcriptomics | DrugBank online. https:\/\/go.drugbank.com\/pharmaco\/transcriptomics?page=3699. Accessed 29 May 2024"},{"issue":"1","key":"1873_CR75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41398-022-01817-0","volume":"12","author":"G Fanelli","year":"2022","unstructured":"Fanelli G et al (2022) Insulinopathies of the brain? genetic overlap between somatic insulin-related and neuropsychiatric disorders. Transl Psychiatry 12(1):59. https:\/\/doi.org\/10.1038\/s41398-022-01817-0","journal-title":"Transl Psychiatry"},{"key":"1873_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105298","volume":"152","author":"C Possidente","year":"2023","unstructured":"Possidente C, Fanelli G, Serretti A, Fabbri C (2023) Clinical insights into the cross-link between mood disorders and type 2 diabetes: a review of longitudinal studies and Mendelian randomisation analyses. Neurosci Biobehav Rev 152:105298. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105298","journal-title":"Neurosci Biobehav Rev"},{"key":"1873_CR77","unstructured":"LINGO2 leucine rich repeat and Ig domain containing 2 [Homo sapiens (human)]-Gene-NCBI. https:\/\/www.ncbi.nlm.nih.gov\/gene\/158038. Accessed 23 May 2024"},{"issue":"11","key":"1873_CR78","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/ng.686","volume":"42","author":"EK Speliotes","year":"2010","unstructured":"Speliotes EK et al (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42(11):937\u2013948. https:\/\/doi.org\/10.1038\/ng.686","journal-title":"Nat Genet"},{"issue":"1","key":"1873_CR79","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1038\/s41598-024-60518-4","volume":"14","author":"Z Pirmoradi","year":"2024","unstructured":"Pirmoradi Z et al (2024) Resveratrol and 1,25-dihydroxyvitamin D decrease Lingo-1 levels, and improve behavior in harmaline-induced essential tremor, suggesting potential therapeutic benefits. Sci Rep 14(1):9864. https:\/\/doi.org\/10.1038\/s41598-024-60518-4","journal-title":"Sci Rep"},{"issue":"9","key":"1873_CR80","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3390\/molecules23092197","volume":"23","author":"A Moore","year":"2018","unstructured":"Moore A, Beidler J, Hong MY (2018) Resveratrol and depression in animal models: a systematic review of the biological mechanisms. Molecules 23(9):2197. https:\/\/doi.org\/10.3390\/molecules23092197","journal-title":"Molecules"},{"key":"1873_CR81","doi-asserted-by":"publisher","first-page":"1172091","DOI":"10.3389\/fnbeh.2023.1172091","volume":"17","author":"R-M Wei","year":"2023","unstructured":"Wei R-M et al (2023) Resveratrol ameliorates maternal separation-induced anxiety- and depression-like behaviors and reduces Sirt1-NF-kB signaling-mediated neuroinflammation. Front Behav Neurosci 17:1172091. https:\/\/doi.org\/10.3389\/fnbeh.2023.1172091","journal-title":"Front Behav Neurosci"},{"issue":"2","key":"1873_CR82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41397-023-00298-8","volume":"23","author":"S-S Huang","year":"2023","unstructured":"Huang S-S et al (2023) Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population. Pharmacogenomics J 23(2):50\u201359. https:\/\/doi.org\/10.1038\/s41397-023-00298-8","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"1873_CR83","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41380-021-01062-9","volume":"26","author":"C Fabbri","year":"2021","unstructured":"Fabbri C et al (2021) Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Mol Psychiatry 26(7):3363\u20133373. https:\/\/doi.org\/10.1038\/s41380-021-01062-9","journal-title":"Mol Psychiatry"},{"key":"1873_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144884","author":"H-J Kang","year":"2020","unstructured":"Kang H-J et al (2020) Genetic markers for later remission in response to early improvement of antidepressants. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21144884","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1873_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-01035-6","volume":"10","author":"QS Li","year":"2020","unstructured":"Li QS, Tian C, Hinds D (2020) Genome-wide association studies of antidepressant class response and treatment-resistant depression. Transl Psychiatry 10(1):1\u201312. https:\/\/doi.org\/10.1038\/s41398-020-01035-6","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1873_CR86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1192\/bjp.2018.256","volume":"214","author":"C Fabbri","year":"2019","unstructured":"Fabbri C et al (2019) Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry 214(1):36\u201341. https:\/\/doi.org\/10.1192\/bjp.2018.256","journal-title":"Br J Psychiatry"},{"issue":"3","key":"1873_CR87","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/tpj.2017.44","volume":"18","author":"C Fabbri","year":"2018","unstructured":"Fabbri C et al (2018) New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics J 18(3):413\u2013421. https:\/\/doi.org\/10.1038\/tpj.2017.44","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"1873_CR88","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1038\/tp.2016.171","volume":"6","author":"QS Li","year":"2016","unstructured":"Li QS, Tian C, Seabrook GR, Drevets WC, Narayan VA (2016) Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response. Transl Psychiatry 6(9):e889\u2013e889. https:\/\/doi.org\/10.1038\/tp.2016.171","journal-title":"Transl Psychiatry"},{"issue":"9","key":"1873_CR89","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jpsychires.2013.05.002","volume":"47","author":"AM Hunter","year":"2013","unstructured":"Hunter AM et al (2013) A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res 47(9):1157\u20131165. https:\/\/doi.org\/10.1016\/j.jpsychires.2013.05.002","journal-title":"J Psychiatr Res"},{"issue":"10","key":"1873_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001326","volume":"9","author":"KE Tansey","year":"2012","unstructured":"Tansey KE et al (2012) Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 9(10):e1001326. https:\/\/doi.org\/10.1371\/journal.pmed.1001326","journal-title":"PLoS Med"},{"issue":"5","key":"1873_CR91","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1176\/appi.ajp.2009.09070932","volume":"167","author":"R Uher","year":"2010","unstructured":"Uher R et al (2010) Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. AJP 167(5):555\u2013564. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09070932","journal-title":"AJP"},{"key":"1873_CR92","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.14.24302836","author":"E Friligkou","year":"2024","unstructured":"Friligkou E et al (2024) Gene discovery and biological insights into anxiety disorders from a multi-ancestry genome-wide association study of > 1.2 million participants. MedRxiv. https:\/\/doi.org\/10.1101\/2024.02.14.24302836","journal-title":"MedRxiv"},{"issue":"1","key":"1873_CR93","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41467-018-03242-8","volume":"9","author":"M Nagel","year":"2018","unstructured":"Nagel M, Watanabe K, Stringer S, Posthuma D, van der Sluis S (2018) Item-level analyses reveal genetic heterogeneity in neuroticism. Nat Commun 9(1):905. https:\/\/doi.org\/10.1038\/s41467-018-03242-8","journal-title":"Nat Commun"},{"issue":"1","key":"1873_CR94","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41398-019-0635-y","volume":"9","author":"J Ward","year":"2019","unstructured":"Ward J et al (2019) Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. Transl Psychiatry 9(1):327. https:\/\/doi.org\/10.1038\/s41398-019-0635-y","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1873_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopsych.2022.06.034","volume":"93","author":"AS Hatoum","year":"2023","unstructured":"Hatoum AS et al (2023) Genome-wide association study shows that executive functioning is influenced by GABAergic processes and is a neurocognitive genetic correlate of psychiatric disorders. Biol Psychiatry 93(1):59\u201370. https:\/\/doi.org\/10.1016\/j.biopsych.2022.06.034","journal-title":"Biol Psychiatry"},{"issue":"7562","key":"1873_CR96","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nature14659","volume":"523","author":"N Cai","year":"2015","unstructured":"Cai N et al (2015) Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature 523(7562):588\u2013591. https:\/\/doi.org\/10.1038\/nature14659","journal-title":"Nature"},{"issue":"10","key":"1873_CR97","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1176\/appi.ajp.2020.19101025","volume":"177","author":"AR Docherty","year":"2020","unstructured":"Docherty AR et al (2020) Genome-wide association study of suicide death and polygenic prediction of clinical antecedents. Am J Psychiatry 177(10):917\u2013927. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19101025","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1873_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-0765-2","volume":"10","author":"W Barkhuizen","year":"2020","unstructured":"Barkhuizen W, Pain O, Dudbridge F, Ronald A (2020) Genetic overlap between psychotic experiences in the community across age and with psychiatric disorders. Transl Psychiatry 10(1):1\u201312. https:\/\/doi.org\/10.1038\/s41398-020-0765-2","journal-title":"Transl Psychiatry"},{"issue":"9","key":"1873_CR99","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41386-021-01044-z","volume":"46","author":"J Bralten","year":"2021","unstructured":"Bralten J et al (2021) Genetic underpinnings of sociability in the general population. Neuropsychopharmacol 46(9):1627\u20131634. https:\/\/doi.org\/10.1038\/s41386-021-01044-z","journal-title":"Neuropsychopharmacol"},{"key":"1873_CR100","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.02.24302211","author":"MO Goodman","year":"2024","unstructured":"Goodman MO et al (2024) Genome-wide association analysis of composite sleep health scores in 413,904 individuals. MedRxiv. https:\/\/doi.org\/10.1101\/2024.02.02.24302211","journal-title":"MedRxiv"},{"issue":"2","key":"1873_CR101","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1176\/appi.ajp.2012.12020237","volume":"170","author":"R Uher","year":"2013","unstructured":"Uher R et al (2013) Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. AJP 170(2):207\u2013217. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12020237","journal-title":"AJP"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01873-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01873-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01873-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:15:58Z","timestamp":1759752958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01873-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1873"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01873-1","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessandro Serretti is or has been a consultant\/speaker for Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier, and Taliaz. Chiara Fabbri was a speaker for Janssen. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}